INFLAMMATORY MARKERS IN END-STAGE RENAL DISEASE PATIENTS ON HAEMODIALYSIS

  • Phebe Lotfy Abdel-Messeih Clinical Pathology Unit, Health Radiation Research Department, National Centers for Radiation Research and Technology (Ncrrt), Egyptian Atomic Energy Authority (Eaea)
  • Manal Mohamed Alkady Clinical Pathology Unit, Health Radiation Research Department, National Centers for Radiation Research and Technology (Ncrrt), Egyptian Atomic Energy Authority (Eaea)
  • Neveen Mostafa Nosseir Clinical Pathology Unit, Health Radiation Research Department, National Centers for Radiation Research and Technology (Ncrrt), Egyptian Atomic Energy Authority (Eaea)
  • Mohamed Said Tawfik Health Radiation Research Department, National Centers for Radiation Research and Technology (Ncrrt), Egyptian Atomic Energy Authority (Aea), Cairo, Egypt
DOI: https://doi.org/10.5937/jomb0-26120
Keywords: CXCL16, iPTH, CRP, ESRD

Abstract


Background: CXC chemokine ligand 16 (CXCL16) is an inflammatory chemokine that mediates renal infiltration of macrophages and activated T cells.
Aim: To investigate serum levels of CXCL16 in patients undergoing hemodialysis and their correlation with other inflammatory markers such as C-reactive protein (CRP) and intact parathyroid hormone (iPTH).
Methods: The study included 40 hemodialysis patients (22 males) and 40 age and gender-matched controls (24 males). Fasting blood sugar (FBS), urea, creatinine, calcium and inorganic phosphorous were assayed in participants using routine methods, glycosylated hemoglobin (HbA1c) by quantitative chromatographic spectrophoto metry, iPTH by chemiluminescent microparticle immuno assay, CRP by nephelometry and CXCL16 by ELISA technique.
Results: Serum CXCL16, CRP, PTH, FBS, urea, and creatinine levels were significantly higher in hemodialysis patients compared to controls (p<0.00001). No statistically significant differences were observed between patients and controls for calcium, phosphorous, and HbA1c. Serum
CXCL16 levels correlated positively with CRP (r=0.956, p<0.00001) and iPTH (r=-0.403, p<0.001). Hemodialysis patients (diabetics or hypertensives) had significantly higher CXCL16 levels compared to non-diabetics or nonhypertensives.

Conclusions: High levels of serum CXCL16, CRP and iPTH reflect the inflammatory status of hemodialysis patients and help avoid complications. Serum CXCL16 could be used as a biomarker together with CRP in these patients.

References

1. National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2 suppl 1): S1–S266.

2. Grill AK, Brimble S. Approach to the detection and management of chronic kidney disease: What primary care providers need to know. Can Fam Physician 2018;64(10): 728–35.

3. GBD 2013 Mortality and Causes of Death Collaborators. A systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385: 117–71.

4. Ortiz A, Covic A, Fliser D, Fouque D, Goldsmith D et al. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet 2014; 383:1831–43.

5. Izquierdo MC, Martin-Cleary C, Fernandez-Fernandez B, Elewa U, Sanchez-Niño MD et al. CXCL16 in kidney and cardiovascular injury. Cytokine Growth Factor Rev 2014;25: 317–25.

6. Aslanian AM, Charo IF. Targeted disruption of the scavenger receptor and chemokine CXCL16 accelerates atherosclerosis. Circulation 2006; 114: 583–90.

7. Shimaoka T, Kume N, Minami M, Hayashida K, Kataoka H et al. Molecular cloning of a novel scavenger receptor for oxidized low-density lipoprotein, SR-PSOX, on macrophages. J Biol Chem 2000; 275: 40663–6.

8. Wu T, Xie C, Wang HW, Zhou XJ, Schwartz et al. Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine
lupus strains and human lupus nephritis. J Immunol 2007; 179: 7166–75.

9. Ležaić V. Serum and urinary biomarkers determination and their significance in diagnosis of kidney disease. J Med Biochem 2010; 29: 288–9

10. Panichi V, Maggiore U, Taccola D, Migliori M, Rizza GM et al. Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in dialytic patients. Nephrol Dial Transplant 2004; 19: 1154–60.

11. Jerin A, Mosa OF, Kališnik JM, Žibert J, Skitek M. Serum Klotho as a marker for early diagnosis of acute kidney injury after cardiac surgery. J Med Biochem 2020; 39:133–9.

12. de Francisco AL. Secondary hyperparathyroidism: review of the disease and its treatment. Clin Ther 2004; 26(12):1976–93.

13. Mitnick MA, Grey A, Masiukiewicz U et al. Parathyroid hormone induces hepatic production of bioactive interleukin- 6 and its soluble receptor, American Journal of Physiology: Endocrinology and Metabolism, vol. 280, no. 3, pp. E405–E412, 2001.

14. Grey A, Mitnick MA, Shapses S, Ellison A, Gundberg C et al. Circulating levels of interleukin-6 and tumor necrosis factor- are elevated in primary hyperparathyroidism and correlate with markers of bone resorption–a clinical research center study. Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 10, pp. 3450–3454, 1996.

15. Emam AA, Mousa SG, Ahmed KY, Al- Azab AA. Inflammatory biomarkers in patients with asymptomatic primary hyperparathyroidism, Medical Principles an Practice 2012; 21: 249–53.

16. Roberts L, Jones TW, Fournier PA. Exercise training and glycemic control in adolescents with poorly controlled type 1 diabetes mellitus. J Pediatr Endocrino Metab 2002; 15(5): 621–7.

17. Sproston NR, Ashworth JJ. Role of C-Reactive Protein at Sites of Inflammation and Infection. Front Immunol 2018; 9: 754.

18. Kritmetapak K, Pongchaiyakul C. Parathyroid Hormone Measurement in Chronic Kidney Disease: From Basics to Clinical Implications. Int J Nephrol 2019; 2019: 5496710. doi: 10.1155/2019/5496710.

19. Heidari B. C-reactive protein and other markers of inflammation in hemodialysis patients. Caspian J Intern Med 2013 Winter; 4(1): 611–6.

20. Nadeem M, Stephen L, Schubert C, Davids MR. Association between periodontitis and systemic inflammation in patients with end-stage renal disease. SADJ 2009; 64: 470–3.

21. Sardenberg C, Suassuna P, Andreoli MC, Watanabe R, Dalboni MA et al. Effects of uraemia and dialysis modality on polymorphonuclear cell apoptosis and function. Nephrol Dial Transplant 2006; 21(1): 160–5.

22. Dinarello CA. Proinflammatory cytokines. Chest 2000; 118(2): 503–8.

23. Baragetti I, El Essawy B, Fiorina P. Targeting Immunity in End-Stage Renal Disease. Am J Nephrol 2017; 45(4): 310–9.

24. Cobo G, Lindholm B, Stenvinkel P. 19. Chronic inflammation in end-stage renal disease and dialysis. Nephrol Dial Transplant 2018; 33(suppl_3): iii35–iii40. doi:10.1093/ndt/gfy175

25. Baralić M, Brković V, Stojanov V, Stanković S, Lalić N, Đurić P, Đukanović L, Kašiković M, Petrović M, Petrović M, Stošović M, Ležaić V. Dual Roles of the Mineral Metabolism Disorders Biomarkers in Prevalent Hemodilysis Patients: In Renal Bone Disease and in Vascular Calcification. J Med Biochem 2019; 38: 134 44.

26. Yuen NK, Ananthakrishnan S, Campbell MJ. Hyper parathyroidism of Renal Disease. Perm J 2016; 20(3): 15–127.

27. Cheng SP, Lee JJ, Liu TP, Yang TL, Chen HH et al. Parathyroidectomy improves symptomatology and quality of life in patients with secondary hyperparathyroidism. Surgery 2014; 155(2): 320–8.

28. Elewa U, Sanchez-Niño MD, Mahillo-Fernández I, Martin-Cleary C, Belen Sanz A et al. Circulating CXCL16 in Diabetic Kidney Disease. Kidney Blood Press Res 2016; 41(5): 663–71.

29. Nazari AD, Sardoo AM, Fard ET, Khorramdelazad H, Hassanshahi G et al. Plasma CXCL16 Level is Associated with Cardiovascular Disease in Iranian Hemodialysis Patients. Biomed & Pharmacol J 2017; 10(1): 01–07.

30. Hu ZB, Chen Y, Gong YX, Gao M, Zhang Y et al. Activation of the CXCL16/CXCR6 Pathway by Inflammation Contributes to Atherosclerosis in Patients with End-stage Renal Disease. Int J Med Sci 2016 20; 13(11): 858–67.

31. Unal HU, Kurt YG, Gok M, Cetinkaya H, Karaman M et al. The Importance of Serum CXCL16 Levels in Patients with Grade III-V Chronic Kidney Disease. Turk Neph Dial Transpl 2014; 23 (3): 234–9.

32. Lin Z, Gong Q, Zhou Z, Zhang W, Liao S. et al. Increased plasma CXCL16 levels in patients with chronic kidney diseases. Eur J Clin Invest 2011; 41(8): 836–45.

33. Lv Y, Hou X, Ti Y, Bu P. Associations of CXCL16/CXCR6 with carotid atherosclerosis in patients with metabolic syndrome. Clin Nutr 2013; 32(5): 849–54.
Published
2020/04/12
Issue
Vol. 39 No. 4 (2020): JMB
Section
Original paper

Copyright (c) 2020 Journal of Medical Biochemistry

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.